Driving Towards Execution – From Theory to Application

 Contributing authors: Carolina Ahrendt, Principal Consultant & Monika Swietlicka, Principal Consultant

As we approach Biocom’s 16^th annual Global Partnering & Investor Conference, Carolina Ahrendt, Principal Consultant in Program Leadership at Halloran, and Monika Swietlicka, Principal Consultant in Regulatory Affairs at Halloran, build upon the first part in the content series, “Biotech After the Reset: Capital, Discipline, and Return of Execution.”

Expectations around execution were a major theme at the J.P. Morgan Healthcare Conference, and in particular, execution is what investors are focusing on. But what exactly does that mean and look like?

It’s going to take the right crew, the right strategy, and the right processes and systems to go from vision to execution – and the ability to adapt as the track evolves. Recent regulatory decisions and shifting evidentiary expectations reinforce finishing strong requires development pathways that are resilient to change, with evidence, manufacturing, and quality strategies designed to withstand review without late-stage resets.

F1 drivers know this well – it’s not about who starts fast, but about who finishes strong. And it certainly takes a relentlessly focused team, not just the driver, to win.

Carolina and Monika share their point of view and provide concrete examples on how to turn the notion of execution into a reality in their latest article.

Halloran Consulting Group, part of ProductLife Group (PLG), partners with early-stage companies, CEOs, and investors to bring deep regulatory and development expertise with global reach, helping teams execute with discipline across critical inflection points.